- Home
- EBS vs MYGN Comparison
EBS vs MYGN Comparison
Compare EBS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBS | MYGN |
|---|---|---|
| Founded | 1998 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.3M | 551.8M |
| IPO Year | 2006 | 1995 |
Fundamental Metrics
Financial Performance| Metric | EBS | MYGN |
|---|---|---|
| Price | $12.05 | $5.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $15.00 | $11.00 |
| AVG Volume (30 Days) | ★ 968.8K | 892.7K |
| Earning Date | 03-02-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | $788,900,000.00 | ★ $825,300,000.00 |
| Revenue This Year | N/A | $0.03 |
| Revenue Next Year | $15.21 | $5.38 |
| P/E Ratio | $8.85 | ★ N/A |
| Revenue Growth | N/A | ★ 0.21 |
| 52 Week Low | $4.02 | $3.76 |
| 52 Week High | $14.06 | $15.47 |
Technical Indicators
Market Signals| Indicator | EBS | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 38.06 |
| Support Level | $10.60 | $5.47 |
| Resistance Level | $12.58 | $6.15 |
| Average True Range (ATR) | 0.79 | 0.36 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 39.60 | 24.33 |
Price Performance
Historical ComparisonAbout EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.